TPST (tempesttx.com) Earnings per share growth rate in current year
The annual EPS percentage difference demonstrates profit dynamics, where the current metric is 54.50. The absence of recurring revenue is driven by Tempest Therapeutics (TPST) focusing on clinical trials for targeted therapy. Developments in treating liver cancer via immune response confirm the growth stage. Meanwhile, competent management effectively attracts venture capital, ensuring high transparency in pipeline reporting.
Analytical breakdowns and data insights for company Tempest Therapeutics (TPST)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt and solvency information:
Total Debt to Equity Ratio Tempest Therapeutics|TPST - Long-Term Debt to Equity|Current Liabilities to Equity tempesttx.com|TPST - Company Aggregate Debts|Debts to Book Value Tempest Therapeutics Corp|TPST - Company Long-Term Debt|Short-Term Debt Volume Tempest Therapeutics|Intermediate Liquidity Ratio tempesttx.com
- earnings and valuation multiples indicators:
TPST - Net Income|Expected Net Income Tempest Therapeutics|TPST - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Tempest Therapeutics Corp|TPST - PEG Multiple|Business Value to Operating Income Before Depreciation Tempest Therapeutics Corp|TPST - Operating profit EBITDA|Net earnings per one share for the last twelve months Tempest Therapeutics|TPST - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months tempesttx.com|TPST - Earnings growth in current year|Earnings growth forecast for next year Tempest Therapeutics
Fundamental valuation:TPST Tempest Therapeutics Inc
For the biotechnology startup Tempest Therapeutics (TPST), which develops targeted oncology therapies, this indicator serves as a measure of the efficiency of innovation capitalization. The metric calculates the percentage deviation of current earnings per share from the same value last year. Analyzing the YoY net income per share trend allows for tracking the company's pace of financial transformation. Growth in this figure confirms the success of drug commercialization, while negative trends signal high R&D expenditures.
Main competitors
BeiGene Ltd. - Earnings per share increase in current year|HALO (Halozyme Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Revolution Medicines Corp RVMD|Net earnings per share growth this year AAPG (Ascentage Pharma Group)|Net earnings per one share growth for the current year CGON|Earnings growth in current year URGN (UroGen Pharma)|Bicara Therapeutics Inc (BCAX) - Earnings per share growth rate in current year|PSNL - Earnings per share growth in current year|Erasca Oncology (ERAS) - Net earnings per share growth this year|Delcath Systems, Inc. (DCTH) - Earnings per share growth in current year|Earnings per share trend in current year YMAB (ymabs.com)|AURA (Aura Biosciences) - Earnings growth in current year|Earnings per share growth rate in current year Candel CADL|Earnings per share growth in current year Accuray Inc. (ARAY)|Expected net earnings per share growth this year sellaslifesciences.com|Actuate Therapeutics, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year CTOR (citiusonc.com)|HURA: Net earnings per share growth this year|Earnings per share increase in current year TARA (Protara Therapeutics Inc)|FATE (Fate Therapeutics Corp) - Net earnings per share growth this year|WHWK: Net earnings per one share growth for the current year|TCRX (TScan Therapeutics Inc) - Earnings growth in current year|CSBR: Earnings per share increase in current year|Earnings growth in current year XBIT|CVM - Earnings per share growth rate in current year|Earnings per share growth in current year OS Therapies Inc OSTX|Earnings per share increase in current year RADX|Artiva - Earnings growth in current year|ANL - Earnings growth in current year|Veru (VERU) - Earnings per share growth in current year|Earnings per share trend in current year XLO (Xilio Therapeutics)|RENB (Renovaro Biosciences) - Earnings growth in current year|Earnings per share growth rate in current year Mural Bio MURA|Net earnings per share growth this year KAPA (Kairos Pharma Ltd)|Earnings growth in current year onkuretherapeutics.com (OKUR)|CytoMed Therapeutics Limited - Net earnings per share growth this year|Net earnings per one share growth for the current year CRIS (Curis Inc.)|Apollomics Corp - Earnings growth in current year|Expected net earnings per share growth this year Tharimmune Corporation THAR|ADVB: Earnings growth in current year|Net earnings per share growth this year genprex.com|Earnings per share growth in current year Calidi Biotherapeutics Inc.|sunshinebiopharma.com (SBFM) - Expected net earnings per share growth this year|Net earnings per share growth this year XBIO (Xenetic Biosciences)|Net earnings per one share growth for the current year SLRX|Earnings per share growth in current year Purple Biotech PPBT|AONC (American Oncology Network Inc) - Earnings per share trend in current year|BGNE - Earnings per share growth in current year|Expected net earnings per share growth this year Checkpoint Therapeutics Inc. CKPT|ELEV (Elevation Oncology) - Net earnings per share growth this year|ICAD: Net earnings per one share growth for the current year|IKNA (Ikena Oncology Inc.) - Earnings growth in current year|Net earnings per share growth this year notablelabs.com (NTBL)|Earnings growth in current year VIRX|Earnings growth in current year MorphoSys Inc (MOR)|Earnings per share growth in current year NAYA Bio NAYA|AAPGV: Earnings per share growth this year
